




The relative strengths and weaknesses of CNS Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CNS Pharmaceuticals Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 13% points. The greatest weakness of CNS Pharmaceuticals Inc is the variable Net Income, reducing the Economic Capital Ratio by 115% points.

The company's Economic Capital Ratio, given in the ranking table, is 140%, being 74% points below the market average of 215%.

Input Variable	Value in 1000 USD
Assets, Current	8,659
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,524
Liabilities, Non-Current	0
Other Assets	36
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	44
Other Revenues	0
Property and Equipment	6.0
Research and Development	9,290
Selling, General and Administrative Expense	5,612

Output Variable	Value in 1000 USD
Assets	8,701
Liabilities	2,524
Expenses	14,902
Revenues	0
Stockholders Equity	6,177
Net Income	-14,858
Comprehensive Net Income	-14,858
BaseVar	13,086
ECR before LimitedLiability	-25%
Economic Capital Ratio	140%